Patents Examined by Michael C. Wilson
  • Method of making human cells expressing OCT4, SOX2, and Nanog using an Ecklonia cava extract
    Patent number: 11186828
    Abstract: The present disclosure relates to a medium composition for r25/eprogramming induced pluripotent stem cells, containing an Ecklonia cava extract. Also, the present disclosure relates to a method for manufacturing induced pluripotent stem cells by using the medium composition. When the medium composition according to the present disclosure is used, induced pluripotent stem cells can be efficiently produced using adipose-derived mesenchymal stem cells safely and easily. The manufactured pluripotent stem cells are differentiable into various cells, and thus can be favorably used as a cell therapeutic agent.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: November 30, 2021
    Assignee: BBHC CO., LTD.
    Inventors: Sang Yeon Lee, Won Ju Jung, Ho Bin Kim, Min Sun Oh, Kye Ho Lee
  • Isolated mammalian somatic cells containing modified RNA encoding OCT4, SOX2, and KLF4
    Patent number: 11186829
    Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: November 30, 2021
    Assignee: Children's Medical Center Corporation
    Inventors: Derrick Rossi, Luigi Warren
  • Method of differentiating umbilical cord tissue into a chondrogenic phenotype
    Patent number: 11179422
    Abstract: Cells derived from postpartum tissue and methods for their isolation and induction to differentiate to cells of a chondrogenic or osteogenic phenotype are provided by the invention. The invention further provides cultures and compositions of the postpartum-derived cells and products such as lysates related thereto. The postpartum-derived cells of the invention and products related thereto have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications, for example, in the treatment of bone and cartilage conditions such as osteoarthritis.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: November 23, 2021
    Assignee: Depuy Synthes Products, Inc.
    Inventors: Laura Brown, Sridevi Dhanaraj, Agnieszka Seyda
  • Porcine animals lacking expression of functional alpha 1, 3 galactosyltransferase
    Patent number: 11172658
    Abstract: The present invention is a porcine animal, tissue, organ, cells and cell lines, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha1,3GT). These animals, tissues, organs and cells can be used in xenotransplantation and for other medical purposes.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: November 16, 2021
    Assignee: Revivicor, Inc.
    Inventors: Carol J. Phelps, David L. Ayares
  • Method for producing photoreceptor cells, retinal pigmented epithelial cells, and retinal organoids
    Patent number: 11168301
    Abstract: A unified cell differentiation protocol for obtaining photoreceptor cells, retinal pigment epithelium, and 3D retinal organoid from pluripotent stem cells is described. Also described are photoreceptor cells, retinal pigmented epithelium, and 3D retinal organoid obtained from pluripotent stem cells. Also described are a pharmaceutical composition and a medicament containing the photoreceptor cells, retinal pigment epithelium, and 3D retinal organoid as described.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: November 9, 2021
    Assignee: EYESTEM RESEARCH PRIVATE LIMITED
    Inventors: Rajarshi Pal, Rajani Battu, Reena Rathod, Harshini Surendran, Kapil Bharti, Deepak Lamba, Dhruv Sareen, Mahendra Rao, Sushma Nanjunda Swamy, Vijay Bhaskar Konala Reddy, Mohanapriya Rajamoorthy
  • Adenoassociated virus vectors for the treatment of lysosomal storage disorders
    Patent number: 11149285
    Abstract: The present invention provides new adenoassociated virus vectors and pharmaceutical compositions containing the same for the treatment of lysosomal storage disorders and specially, for the treatment of mucopolysaccharidoses Type IIIB.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: October 19, 2021
    Assignees: UNIVERSITAT AUTÓNOMA DE BARCELONA, ESTEVE PHARMACEUTICALS, S.A.
    Inventors: M Fàtima Bosch Tubert, M Virginia Haurigot Mendoça, Albert Ribera Sanchez
  • Method of using a genetically modified mouse that expresses a humanized CTLA-4 gene
    Patent number: 11096383
    Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric CTLA-4, and methods of use thereof.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: August 24, 2021
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yanan Guo, Yang Bai, Jiawei Yao, Chengzhang Shang, Rui Huang
  • Vector for targeting the human Rosa26 gene
    Patent number: 11078494
    Abstract: The invention provides a method for generating a transgenic eukaryotic cell population having a modified human Rosa26 locus, which method includes introducing a functional DNA sequence into the human Rosa26 locus of starting eukaryotic cells. Also provided are targeting vectors useful in the method, as well as a cell population and a transgenic non-human animal comprising a modified human Rosa26 locus. Finally, the invention provides an isolated DNA sequence corresponding to the human Rosa26 locus.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: August 3, 2021
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Gordon Keller, Stefan Irion, Herve Luche, Paul Gadue, Hans J. Fehling
  • Method of differentiating human pluripotent cells into cardiac fibroblasts
    Patent number: 11072780
    Abstract: Methods for generating high-yield, high-purity cardiac fibroblasts are described. Differentiation methods comprising chemically defined culture conditions and methods for in vitro maintenance of human pluripotent stem cell-derived cardiac fibroblasts are also provided.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: July 27, 2021
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Timothy Joseph Kamp, Jianhua Zhang
  • Genetically modified non-human animal with human or chimeric CTLA-4
    Patent number: 11071290
    Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric CTLA-4, and methods of use thereof.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: July 27, 2021
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yanan Guo, Yang Bai, Jiawei Yao, Chengzhang Shang, Rui Huang
  • Methods for the treatment of Danon disease and other disorders of autophagy
    Patent number: 11065347
    Abstract: This disclosure provides gene therapy vectors comprising a polynucleotide encoding one or more isoforms of lysosome-associated membrane protein 2 (LAMP-2), and methods of using such gene therapy vectors for the treatment of Danon disease and other autophagy disorders.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: July 20, 2021
    Assignee: The Regents of the University of California
    Inventors: Eric D. Adler, Bradley Nelson, Sherin Hashem
  • Method of encapsulating pancreatic islet cells introduced to siRNA against PHLDA3
    Patent number: 11045425
    Abstract: The present invention provides a method for preparing a graft material containing organ or tissue cells, the cells including cells having inhibited PHLDA3 expression.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: June 29, 2021
    Assignees: Kyoto University, Tohoku University, Kuraray Co., Ltd.
    Inventors: Shoichiro Sumi, Rieko Ohki, Naoaki Sakata
  • Method for the treatment of lysosomal storage diseases
    Patent number: 11040115
    Abstract: Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for treatment and/or prevention of a lysosomal storage disease.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: June 22, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Edward J. Rebar
  • Transgenic chicken for production of antibodies having a common light chain
    Patent number: 11033009
    Abstract: This disclosure provides, among other things, a transgenic animal and a method of using the same to make antibodies that have a common light chain. In certain embodiments, the transgenic animal may comprising a genome comprising a common light chain transgene, wherein the common light chain transgene comprises a non-immunoglobulin light-chain promoter and a common light-chain coding sequence. In certain embodiments, the common light chain is constitutively expressed.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 15, 2021
    Assignee: CRYSTAL BIOSCIENCE INC.
    Inventors: William Don Harriman, Robert Etches, Philip A. Leighton
  • Humanized low affinity FC?R mouse cells
    Patent number: 11020495
    Abstract: Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity Fc?R locus, and wherein the mouse is capable of expressing a functional FcR?-chain. Genetically modified mice are described, including mice that express low affinity human Fc?R genes from the endogenous Fc?R locus, and wherein the mice comprise a functional FcR?-chain. Genetically modified mice that express up to five low affinity human Fc?R genes on accessory cells of the host immune system are provided.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: June 1, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Naxin Tu, Cagan Gurer, Sean Stevens, Andrew J. Murphy
  • Animal study model for cancer
    Patent number: 11006620
    Abstract: The invention concerns a gallinacean embryo in which cancer cells have been grafted within the embryo tissue, characterised in that the embryo is at a developmental stage between the HH10 and HH25 stages at the time of the grafting, wherein said cancer cells are not neuroblastoma cells and said cells form tumors inside the embryo.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: May 18, 2021
    Assignees: UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
    Inventors: Valerie Castellani-Lincontang, Celine Delloye-Bourgeois
  • Mammalian alveolar macrophages derived from pluripotent cells
    Patent number: 11001806
    Abstract: Alveolar-like macrophages and a method for generating alveolar-like macrophages from hemangioblasts is provided. The method comprises the steps of: i) culturing the hemangioblasts in a hematopoietic-inducing medium comprising vascular endothelial growth factor (VEGF), stem cell factor (SCF) and interleukin-3 (IL-3) for a sufficient period of time to generate macrophages, and ii) culturing the macrophages in an alveolar macrophage-inducing medium comprising granulocyte macrophage colony stimulating factor (GM-CSF), and optionally macrophage colony stimulating factor (M-CSF), under suitable conditions and for a sufficient period of time to yield alveolar-like macrophages.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: May 11, 2021
    Assignee: The Hospital for Sick Children
    Inventors: Martin Post, Michael Litvack
  • SynP160, a promoter for the specific expression of genes in rod photoreceptors
    Patent number: 10994026
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 300 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: May 4, 2021
    Assignee: Friedrich Miescher Institute for Biomedical Research
    Inventors: Dominik Hartl, Josephine Juettner, Arnaud Krebs, Botond Roska, Dirk Schuebeler
  • Isolated human mesenchymal stem cell expressing a bispecific antibody that binds CD33 and CD3 and method of using to treat cancer
    Patent number: 10941202
    Abstract: The invention concerns pluri- or multipotent stem cells (SCs), e.g. human pluri- or multipotent stem cells (hSCs) engineered to express a multispecific antibody and which further express, on their surface, a human immune cell co-stimulatory ligand or an active fragment thereof.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: March 9, 2021
    Assignee: GEMOAB MONOCLONALS GMBH
    Inventor: Armin Ehninger
  • Genetically modified mice expressing humanized CD47
    Patent number: 10918095
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD47, and methods of use thereof.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: February 16, 2021
    Assignee: Beijing Biocytogen Co., Ltd
    Inventors: Yuelei Shen, Yang Bai, Jian Ni, Rui Huang, Chengzhang Shang, Yanan Guo